Aclaris Therapeutics (ACRS) Change in Accured Expenses (2014 - 2026)

Aclaris Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 72.6% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$81000.0, a 96.1% increase from a year earlier, with the FY2025 full-year figure at -$8.1 million, down 105.4% from the prior year.
• Change in Accured Expenses slipped to -$3.0 million in Q1 2026 per ACRS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $11.6 million in Q4 2024 and bottomed at -$12.9 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $399000.0 (2025), against an average of -$146000.0.
• Across the five-year window, Change in Accured Expenses jumped 928.49% in 2023 and slumped 1012.67% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$681000.0 in 2022, then soared by 928.49% to $5.6 million in 2023, then soared by 105.1% to $11.6 million in 2024, then sank by 89.19% to $1.3 million in 2025, then sank by 341.89% to -$3.0 million in 2026.
• Per Business Quant, the three latest ACRS Change in Accured Expenses figures stand at -$3.0 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025).